Trial Profile
Open-Label Extension Study to Evaluate the Efficacy and Safety of FG-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2021
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors FibroGen
- 01 Sep 2021 Phase of the study is changed from phase 2/3 to phase 2.
- 24 Jun 2020 Status changed from recruiting to completed.
- 15 Apr 2016 Study design is changed from observational to Interventional as per ClinicalTrials.gov.